This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirk, G. Articles by Belch, J. J. Search for Related Content PubMed PubMed Citation Articles by Kirk, G. Articles by Belch, J. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL Social Bookmarking                         What's this?

Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment

Section of Vascular Medicine and Biology, University Departments of Medicine, Dundee, UK

Margaret McLaren

Section of Vascular Medicine and Biology, University Departments of Medicine, Dundee, UK

Andrew H Muir

Section of Vascular Medicine and Biology, University Departments of Medicine, Dundee, UK

Peter A Stonebridge

Surgery, Ninewells Hospital and Medical School, Dundee, UK

Jill JF Belch

Section of Vascular Medicine and Biology, University Departments of Medicine, Dundee, UK

At sites of thrombosis and vascular injury, interactions occur among platelets, leucocytes and endothelial cells. Patients with peripheral arterial occlusive disease (PAOD) have been shown to have raised total serum cholesterol and serum triglycerides and increased sP-selectin levels when compared with controls. A total of 31 patients with PAOD and hypercholesterolaemia took part in this three-staged study. Soluble P-selectin (sP-selectin) levels were significantly lowered after 12 weeks of fluvastatin treatment (157.0 ng/ml versus 113.77 ng/ml, p = 0.01), whereas 12 weeks of placebo treatment had no statistically significant effect on sP-selectin levels (150.0 ng/ml versus 139.4 ng/ml). An unpaired t-test almost reached statistical significance (p = 0.051) when the levels by which sP-selectin fell after 12 weeks of active or placebo treatment were compared. The placebo group was then put onto long-term, active treatment and sP-selectin levels were significantly lowered by fluvastatin when compared to pre-treatment levels (150.0 ng/ml versus 110.0 ng/ml, p = 0.03). By lowering the levels of P-selectin, fluvastatin may not only attenuate atherosclerotic progression but may also decrease the platelet activation associated with PAOD.

Key Words: atherosclerosis • cholesterol • endothelium • peripheral arterial occlusive disease • platelets

Vascular Medicine, Vol. 4, No. 1, 23-26 (1999)
DOI: 10.1177/1358836X9900400104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Galkina and K. Ley Double Jeopardy: How Soluble P-Selectin Activates Leukocytes in Peripheral Arterial Occlusive Disease Circ. Res., January 6, 2006; 98(1): 12 - 14. [Full Text] [PDF]

				J. M McKenney Potential Nontraditional Applications of Statins Ann. Pharmacother., July 1, 2003; 37(7): 1063 - 1071. [Abstract] [Full Text] [PDF]

				D E Newby, F N Witherow, R A Wright, P Bloomfield, C A Ludlam, N A Boon, K A A Fox, and D J Webb Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo Heart, January 1, 2002; 87(1): 48 - 53. [Abstract] [Full Text] [PDF]

				W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]